What is HC Wainwright’s Estimate for CGEM FY2025 Earnings?

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – HC Wainwright lifted their FY2025 EPS estimates for Cullinan Therapeutics in a research report issued on Thursday, November 6th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($3.75) per share for the year, up from their previous forecast of ($4.01). HC Wainwright currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.04) per share. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q4 2025 earnings at ($0.89) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.95) EPS, Q3 2026 earnings at ($0.98) EPS, Q4 2026 earnings at ($1.01) EPS and FY2026 earnings at ($3.86) EPS.

Other equities analysts have also issued research reports about the company. BTIG Research restated a “buy” rating and issued a $32.00 target price on shares of Cullinan Therapeutics in a research note on Wednesday, September 10th. Weiss Ratings restated a “sell (e+)” rating on shares of Cullinan Therapeutics in a research note on Wednesday, October 8th. Zacks Research raised Cullinan Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 16th. Finally, Morgan Stanley cut their price target on shares of Cullinan Therapeutics from $35.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, August 18th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $26.00.

Cullinan Therapeutics Trading Down 2.2%

NASDAQ:CGEM opened at $7.19 on Monday. The company has a market capitalization of $424.74 million, a P/E ratio of -2.17 and a beta of -0.07. Cullinan Therapeutics has a 12 month low of $5.68 and a 12 month high of $17.50. The firm has a fifty day simple moving average of $7.05 and a 200-day simple moving average of $7.63.

Cullinan Therapeutics (NASDAQ:CGEM) last released its earnings results on Thursday, November 6th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.18.

Insider Activity at Cullinan Therapeutics

In related news, major shareholder Lynx1 Capital Management Lp bought 165,667 shares of the company’s stock in a transaction that occurred on Tuesday, October 28th. The shares were purchased at an average cost of $8.40 per share, with a total value of $1,391,602.80. Following the completion of the acquisition, the insider directly owned 8,963,500 shares in the company, valued at approximately $75,293,400. The trade was a 1.88% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders bought a total of 1,874,057 shares of company stock valued at $13,325,286 in the last quarter. 7.16% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cullinan Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Brooklyn Investment Group acquired a new position in shares of Cullinan Therapeutics in the 1st quarter valued at $34,000. Tower Research Capital LLC TRC increased its holdings in Cullinan Therapeutics by 44.6% in the second quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company’s stock valued at $62,000 after buying an additional 2,523 shares in the last quarter. SG Americas Securities LLC purchased a new position in Cullinan Therapeutics in the third quarter valued at $62,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Cullinan Therapeutics in the second quarter worth about $84,000. Finally, Inscription Capital LLC purchased a new stake in shares of Cullinan Therapeutics during the 3rd quarter worth about $67,000. Hedge funds and other institutional investors own 86.31% of the company’s stock.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.